Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen uPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, Q2 2026
335
Period ended Jun 30, 2026
Change on a year earlier
+90.3%
176 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 335 | +90.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 262 | +187.9% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 233 | +130.7% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 155 | +46.2% | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 176 | +91.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 91 | +13.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 101 | +55.4% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 106 | – | Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 92 | – | Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 80 | – | Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 65 | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Breakdown
What makes up uplizna (inebilizumab-cdon — nmosd & igg4-related disease) — worldwide product sales ($m)
Cite this data
StockData. (2026). Amgen UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Worldwide product sales ($M) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_uplizna_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.